Vasopeptidase inhibitors

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 3, Issue 2, 2002, Pages 90-95

  Sagnella, Giuseppe A ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Angiotensin II; Clinical trials; Natriuretic peptides; Vasopeptidase inhibitors

Indexed keywords

7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FASIDOTRIL; GEMOPATRILAT; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C; OMAPATRILAT; SAMPATRILAT; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR; Z 13752A; ENZYME INHIBITOR;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HYPERTENSION; HYPERVOLEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; REVIEW; DRUG ANTAGONISM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; NEPRILYSIN;

EID: 0036614673     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2002.023     Document Type: Review

References (54)

1. Atrial natriuretic peptide mimetics and vasopeptidase inhibitors
2. Natriuretic peptides
3. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones
4. Neutral endopeptidase-24.11 inhibitors: From analgesics to antihypertensives?
5. Neutral endopeptidase 24.11: Structure, inhibition and experimental clinical pharmacology
6. Endopeptidase-24.11 and its inhibitors: Potential therapeutic agents for edematous disorders and hypertension
7. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects
8. The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans
9. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man
10. Hormonal and renal responses to neutral endopeptidase inhibition in normal humans on a low and on a high sodium intake
11. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure
12. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure
13. Chronic inhibition of endopeptidase 24.11 in essential hypertension: Evidence for enhanced atrial natriuretic peptide and angiotensin II
14. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin
15. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme
16. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension
17. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus
18. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure
19. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure
20. Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients
21. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension
22. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): Rational design, properties, and potential cardiovascular applications of glycopril and alatriopril
23. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats
24. Effects of omapatrilat in low, normal, and high renin experimental hypertension
25. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure
26. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans
27. The cardiac hormone atrial natriuretic peptide mediates hemodynamic actions of dual enzyme inhibition in early left ventricular dysfunction
28. Bradykinin metabolism in the postinfarcted rat heart: Role of ACE and neutral endopeptidase 24.11
29. Omapatrilat increases plasma concentration of adrenomedullin in salt-sensitive hypertensives
30. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100, 240, on endocrine and renal functions in healthy volunteers
31. Omapatrilat versus lisinopril: Efficacy and neurohormonal profile in salt-sensitive hypertensive patients
32. Omapatrilat is not a diuretic: Single-and multiple-dose analysis of the urinary excretion of sodium
33. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure
34. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
35. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects
36. Vasopeptidase inhibitors: Incorporation of a geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides
37. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase
38. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans
39. Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction
40. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and volunteers
41. The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin
42. The importance of early intervention in CHF- signs and symptom relief
43. Monotherapy treatment success rate of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril and amlodipine in mild to moderate hypertension
44. Efficacy and safety of omapatrilat, a vasopeptidase inhibitor
45. Antihypertensive efficay of omapatrilat, a vasopeptidase inhibitor, compared with lisonopril
46. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
47. Renal function, neurohormonal activation and survival in patients with chronic heart failure
48. Vasopeptidase inhibition and angio-oedema
49. Plasma bradykinin in angio-oedema
50. Potential role of mixed ACE and neutral endopeptidase inhibitor in the treatment of heart failure
51. Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: Interaction with cardiac cytokine expression
52. Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial